Biomarkers Come of Age in Clinical Pharmacology

Affiliations

Editorial

Kathleen M Giacomini. Clin Pharmacol Ther. 2023 May.

. 2023 May;113(5):945-947.

doi: 10.1002/cpt.2880.

¹ Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.

No abstract available

Comment on

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.
Biomarkers Definitions Working Group.. Biomarkers Definitions Working Group.. Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989. Clin Pharmacol Ther. 2001. PMID: 11240971 Review. No abstract available.

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
1. Strimbu, K. & Tavel, J.A. What are biomarkers? Curr. Opin. HIV AIDS 5, 463-466 (2010).
1. https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarke.... Accessed 22 February 2023
1. Rodrigues, A.D. Reimagining the framework supporting the static analysis of transporter drug interaction risk; integrated use of biomarkers to generate pan-transporter inhibition signatures. Clin. Pharmacol. Ther. 113, 986-1002 (2023).
1. Lin, J. et al. Effect of hepatic impairment on OATP1B activity: quantitative pharmacokinetic analysis of endogenous biomarker and substrate drugs. Clin. Pharmacol. Ther. 113, 1058-1069 (2023).